A 3D printed medication (also called 3D printed medicine, 3D printed pharmaceutical, or 3D printed drug) is a customized medication created using 3D printing techniques, such as 3D printed tablets.[1] It allows for precise control over the composition and dosage of drugs, enabling the production of personalized medicine tailored to an individual's specific needs, such as age, weight, and medical condition. This approach can be used to improve the effectiveness of drug therapies and to reduce side effects.[2]

Applications

edit

Pharmaceutical tablets

edit

The most common application of 3D printing in pharmaceuticals is the production of tablets and capsules. 3D printing offers precise dosing, the ability to design tablets with improved release profiles, and the capability to combine multiple medications into a single tablet.[3] Current developments primarily focus on 3D printing drugs for pediatric, geriatric, psychiatry, and neurology patients, where dosage adjustments are often necessary based on a patient's condition, and patient adherence is a challenge.[4][5] The first 3D-printed tablet to receive FDA approval was Spritam (levetiracetam), an anti-epileptic medication.[6]

Various designs have been invented to enable different drug release profiles. 3D printing protocols have been developed to print tablets with immediate-release and modified release profiles. The order and geometric orientation of layers in a tablet, the shape of tablets, and the excipients used determine the release profile of the active pharmaceutical ingredients.[7]

Drug-functionalized materials

edit

In addition to 3D drug printing which aims at printing drug formulations, 3D printing can be used to fabricate materials functionalized by drugs, e.g., antibiotics or angiogenic agents.[8] This area which is a part of biomaterials engineering, aims at products such as adhesive patches for wound healing, hydrogel, and non-hydrogel implants, rather than tablets or capsules. As such, this field is distinct from 3D drug printing discussed above.

Techniques

edit

The techniques used for printing medication typically involve various additive manufacturing methods, including:

These techniques offer various advantages and can be tailored to specific drug formulations and manufacturing requirements.

Binder jet

edit

The binder jet approach begins by spreading a fine layer of powder onto the platform using a roller.[9] Subsequently, a removable printhead sprays droplets, selectively binding the powder to create the desired structure. The platform is then lowered, and a new layer of powder is spread while the printhead continues to deposit droplets. This layer-by-layer printing method repeats until the entire object is formed. Finally, the finished products are extracted, the excess powder is removed, and any necessary post-processing is performed.[10] The printing inks typically contain only the binder, while the powder bed contains the Active Pharmaceutical Ingredient (API) and other supplementary ingredients. In some cases, the API can be introduced into the powder bed as a solution or in the form of nanoparticle suspension. It's worth noting that BJ-3DP technology is not limited to APIs with high water solubility. For APIs that are poorly soluble in water, their solubility can be enhanced through pre-treatment methods, although there is relatively limited research in this area.[11]

Fused deposition modeling

edit

Fused deposition modeling technology[12] was made available to the public domain in 2009, and is currently a commonly used approach to 3D drug printing. The process begins with a polymer filament that incorporates the drug. This filament is fed through a high-temperature nozzle by two rollers, controlled by computer software to print. Once one layer is complete, the printing platform initiates the next layer. This sequence continues until the entire printing process is finished.[13]

Melt extrusion deposition

edit

Mult extrusion deposition 3D printing leverages a combination of hot melt extrusion and fused deposition modeling technologies. The process is initiated by introducing active pharmaceutical ingredients (API) and various excipients into separate feeding devices. These materials are then subjected to heat and intense shearing within the hot melt extrusion system, resulting in a uniform molten state.[14] Subsequently, this molten material is delivered to the hot melt extrusion module. The printing stations coordinate their actions, allowing for the amalgamation of diverse molten materials, which are then deposited layer by layer onto the printing platform. Precise control of pressure and temperature results in the creation of 3D-printed preparations that closely replicate the desired structure.

Selective laser sintering

edit

Selective laser sintering (SLS) uses powder as a raw material and a laser as energy input to fuse particles together. This technique has been investigated for the production of medication in various studies with no introduction to the market so far. Since most pharmaceutical substances are powders at room temperature, SLS requires no material preparation steps. Moreover, basically no post-processing is needed due to the dry printing conditions and lack of supporting structures. Disadvantages are the high chance of cross-contamination when printing different substances in the same printer, as well as high print failure rate with substances that are not optimized for SLS printing.[15]

Semisolid solid extrusion

edit

Semisolid solid extrusion, is an additive manufacturing technique that builds objects layer by layer. In SSE, an extrusion head follows a predefined path, depositing semisolid material to create each layer, and gradually stacking them to form the final product.[16] SSE is conceptually similar to Fused Deposition Modeling (FDM), with a key distinction: the material used in SSE is semisolid at room temperature. This means that precise temperature control is essential during the printing process to prevent excessive softening of the material due to high temperatures, ensuring it maintains its intended shape.

To facilitate this process, a dedicated syringe contains the semisolid print material. The extrusion of the material can be accomplished using various methods, such as pneumatic pressure, mechanical energy, or an electromagnetic system. This technology allows for the creation of complex structures and customized objects by precisely controlling the deposition of semisolid material layer by layer.[17]

Stereolithography

edit

Stereolithography technology operates on the principle of photopolymerization, utilizing laser scanning to solidify liquid resin and build 3D-printed objects layer by layer.[18] The printing process can be configured to work either from the top to the bottom or vice versa, depending on the printer's setup. To initiate printing, the liquid photopolymer resin is poured into a reservoir, and a scanning mirror focuses a laser beam onto the resin's surface, creating a focused light spot. This light spot solidifies the resin within its swept area. Once a scanning layer is completed, the printing platform lowers by one layer's height, and a squeegee levels the resin surface for the subsequent layer of printing. This process continues until the object is fully formed. Afterward, the finished product is extracted, and any excess resin and support structures are removed. SLA is particularly useful for thermo-labile drugs.[19]

See also

edit

References

edit
  1. ^ Capel, Andrew J.; Rimington, Rowan P.; Lewis, Mark P.; Christie, Steven D. R. (21 November 2018). "3D printing for chemical, pharmaceutical, and biological applications". Nature Reviews Chemistry. 2 (12): 422–436. doi:10.1038/s41570-018-0058-y. S2CID 187087516.
  2. ^ "Revolution in Pharmacy: 3D Printed Medicines". March 14, 2023.
  3. ^ Wang, S; Chen, X; Han, X; Hong, X; Li, X; Zhang, H; Li, M; Wang, Z; Zheng, A (26 January 2023). "A Review of 3D Printing Technology in Pharmaceutics: Technology and Applications, Now and Future". Pharmaceutics. 15 (2): 416. doi:10.3390/pharmaceutics15020416. PMC 9962448. PMID 36839738.
  4. ^ M, Michael (29 August 2023). "Research Begins On 3D Printed Drugs For Pediatric Care". 3Dnatives.
  5. ^ Shaikhnag, Ada (11 October 2023). "MB Therapeutics uses 3D printing to create personalized medicine for children". 3D Printing Industry.
  6. ^ "First 3D-printed pill". Nature Biotechnology. 33 (10): 1014. October 2015. doi:10.1038/nbt1015-1014a. PMID 26448072. S2CID 28321356.
  7. ^ "Shape matters: how 3D printing can optimize drug release and effectiveness". IO. 1 August 2023.
  8. ^ Zhang, Yue; Wang, Chao (June 2022). "Recent advances in 3D printing hydrogel for topical drug delivery". MedComm – Biomaterials and Applications. 1 (1). doi:10.1002/mba2.11.
  9. ^ Wu, Benjamin M.; Borland, Scott W.; Giordano, Russell A.; Cima, Linda G.; Sachs, Emanuel M.; Cima, Michael J. (1 June 1996). "Solid free-form fabrication of drug delivery devices". Journal of Controlled Release. 40 (1): 77–87. doi:10.1016/0168-3659(95)00173-5. ISSN 0168-3659.
  10. ^ Wang, Yingya; Müllertz, Anette; Rantanen, Jukka (14 July 2022). "Additive Manufacturing of Solid Products for Oral Drug Delivery Using Binder Jetting Three-Dimensional Printing". AAPS PharmSciTech. 23 (6): 196. doi:10.1208/s12249-022-02321-w. ISSN 1530-9932. PMID 35835970. S2CID 250560533.
  11. ^ Chen, Grona; Xu, Yihua; Chi Lip Kwok, Philip; Kang, Lifeng (1 August 2020). "Pharmaceutical Applications of 3D Printing". Additive Manufacturing. 34: 101209. doi:10.1016/j.addma.2020.101209. ISSN 2214-8604. S2CID 219040532.
  12. ^ Cailleaux, Sylvain; Sanchez-Ballester, Noelia M.; Gueche, Yanis A.; Bataille, Bernard; Soulairol, Ian (10 February 2021). "Fused Deposition Modeling (FDM), the new asset for the production of tailored medicines". Journal of Controlled Release. 330: 821–841. doi:10.1016/j.jconrel.2020.10.056. ISSN 0168-3659. PMID 33130069.
  13. ^ Goyanes, Alvaro; Scarpa, Mariagiovanna; Kamlow, Michael; Gaisford, Simon; Basit, Abdul W.; Orlu, Mine (15 September 2017). "Patient acceptability of 3D printed medicines". International Journal of Pharmaceutics. 530 (1): 71–78. doi:10.1016/j.ijpharm.2017.07.064. ISSN 0378-5173. PMID 28750894.
  14. ^ Zheng, Yu; Deng, Feihuang; Wang, Bo; Wu, Yue; Luo, Qing; Zuo, Xianghao; Liu, Xin; Cao, Lihua; Li, Min; Lu, Haohui; Cheng, Senping; Li, Xiaoling (1 June 2021). "Melt extrusion deposition (MED) 3D printing technology – A paradigm shift in design and development of modified release drug products". International Journal of Pharmaceutics. 602: 120639. doi:10.1016/j.ijpharm.2021.120639. ISSN 0378-5173. PMID 33901601. S2CID 233409105.
  15. ^ Tikhomirov, Evgenii (2023). "Selective laser sintering for 3D printing of medications". {{cite journal}}: Cite journal requires |journal= (help)
  16. ^ van Kampen, Eveline E. M.; Ayyoubi, Sejad; Willemsteijn, Luc; van Bommel, Kjeld J. C.; Ruijgrok, Elisabeth J. (January 2023). "The Quest for Child-Friendly Carrier Materials Used in the 3D Semi-Solid Extrusion Printing of Medicines". Pharmaceutics. 15 (1): 28. doi:10.3390/pharmaceutics15010028. ISSN 1999-4923. PMC 9865971. PMID 36678657.
  17. ^ Khaled, Shaban A.; Burley, Jonathan C.; Alexander, Morgan R.; Yang, Jing; Roberts, Clive J. (30 October 2015). "3D printing of tablets containing multiple drugs with defined release profiles". International Journal of Pharmaceutics. 494 (2): 643–650. doi:10.1016/j.ijpharm.2015.07.067. ISSN 0378-5173. PMID 26235921.
  18. ^ Deshmane, Subhash; Kendre, Prakash; Mahajan, Hitendra; Jain, Shirish (2 September 2021). "Stereolithography 3D printing technology in pharmaceuticals: a review". Drug Development and Industrial Pharmacy. 47 (9): 1362–1372. doi:10.1080/03639045.2021.1994990. ISSN 0363-9045. PMID 34663145. S2CID 239025849.
  19. ^ Dizon, John Ryan C.; Espera, Alejandro H.; Chen, Qiyi; Advincula, Rigoberto C. (1 March 2018). "Mechanical characterization of 3D-printed polymers". Additive Manufacturing. 20: 44–67. doi:10.1016/j.addma.2017.12.002. ISSN 2214-8604.